Fig. 7

Vimentin immunohistochemistry. b After the sham procedure (Sham), anti-vimentin (green) immunoreactivity can be seen in the end feet of Müller cells (arrow heads; see also c and f) within the ganglion cell layer (GCL) as well as their processes are also immunolabeled in the IPL (arrows; see also c and f), INL and ONL. c, f Compared to the sham retina, there was a considerable enhancement of the anti-vimentin immunolabeling after ischemia and pre-administration or post-administration of vehicle (Vehicle+I/R or I/R + Vehicle). d, e, g This enhancement was obviously counteracted by pre-administration of 0.5 g/kg/day (DNL0.5 + I/R), or 1 g/kg/day of DNL (DNL1.0 + I/R), or post-administration of 1 g/kg/day of DNL (I/R + DNL1.0). GFAP immunohistochemical study. After the sham procedure (Sham; i), the Müller cells displayed GFAP immunoreactivity at their end feet within the GCL (arrow heads; see also j and m), and at their processes in the IPL (arrows; see also j and m), INL and ONL. Compared to the Sham retina, anti-GFAP immunolabeling was enhanced after ischemia and pre-administration/post-administration of vehicle (Vehicle+I/R, j; I/R + Vehicle, m). This enhancement was mitigated by pre-administration of 0.5 g/kg/day (DNL0.5 + I/R; k) or 1 g/kg/day of DNL (DNL1.0 + I/R; l), or post-administration of 1 g/kg/day of DNL (I/R + DNL1.0; n). a, h DAPI (blue) was used to counterstain cell nuclei in the sham retina. DNL, Dendrobium nobile Lindley. GFAP, glial fibrillary acidic protein; IPL, inner plexiform layer; INL, inner nuclear layer; ONL, outer nuclear layer; DAPI, 4,6-diamidine-2-phenylindole dihydrochloride. Scale bar = 25 μm